Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0~102.0% Hale Hana

ʻO Lenvatinib Mesylate (CAS: 857890-39-2) he mea hoʻopaneʻe waha a me ka nui o ka VEGFR1-3, FGFR1-4, PDGFR, KIT, a me RET, me nā hana antitumor ikaika.ʻO Lenvatinib Mesylate kahi mea hoʻopaneʻe tyrosine kinase (RTK) i loaʻa ke koho no VEGFR2.Hōʻike ia i ka hana antineoplastic, a ua hōʻike ʻia no ka mālama ʻana i nā poʻe maʻi me ka maʻi hou a i ʻole metastatic, holomua, radioactive iodine (RAI) -refractory differentiated thyroid cancer.Ua ʻae ʻia ʻo Lenvatinib Mesylate e ka US Food and Drug Administration (FDA) ma Feb 13, 2015, a laila ʻae ʻia e Pharmaceuticals and Medical Devices Agency of Japan (PMDA) ma Mar 26, 2015, a ʻae ʻia e European Medicine Agency (EMA) ma Mei 28, 2015. Ua kūkulu ʻia a kūʻai ʻia ʻo Lenvima® e Eisai.ʻO Lenvatinib Mesylate he mea hoʻopaneʻe waha waha tyrosine kinase inhibitor me kahi ʻano hoʻopaʻa kūʻokoʻa e hoʻokaʻawale i nā hana kinase o nā mea hoʻokipa vascular endothelial growth factor (VEGF), me ka hoʻohui ʻana i nā tyrosine kinases pili proangiogenic a me oncogenic i manaʻo ʻia e komo i ka hoʻonui ʻana o ka tumor. .Hōʻike ʻia ia no ka mālama ʻana i ka radioiodine-refractory differentiated thyroid cancer holomua.ʻO LenvimaHoʻohana ʻia ʻo ia e mālama i ka maʻi maʻi thyroid ʻokoʻa (DTC), kahi ʻano o ka maʻi maʻi thyroid ʻaʻole hiki ke mālama hou ʻia me ka iodine radioactive a ke holomua nei.Hoʻohana ʻia ʻo LENVIMA me kekahi lāʻau ʻē aʻe i kapa ʻia ʻo everolimus no ka mālama ʻana i nā pākeke me kahi ʻano maʻi maʻi maʻi ʻaʻai i kapa ʻia ʻo advanced renal cell carcinoma (RCC) ma hope o hoʻokahi papa o ka mālama ʻana me kekahi lāʻau anti-cancer.